FLA-797 是一种可穿透血脑屏障的多巴胺 D2 受体阻滞剂,对多巴胺 D1 受体亲和力极低,可选择性结合并阻断突触后多巴胺 D2 受体,诱导雄性大鼠出现僵住症,阻断多巴胺激动剂诱导的雄性大鼠体温过低,对雄性大鼠中 Remoxipride (MS-M25923) 的多巴胺 D2 受体阻断活性仅起微弱作用,无法模拟 Remoxipride 的非典型抗精神病药特征,可用于精神障碍的研究。
产品编号: MS-G19968 CAS No.: 84226-14-2 分子式: C15H21BrN2O3 分子量: 357.24
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

FLA-797 是一种可穿透血脑屏障的多巴胺 D2 受体阻滞剂,对多巴胺 D1 受体亲和力极低,可选择性结合并阻断突触后多巴胺 D2 受体,诱导雄性大鼠出现僵住症,阻断多巴胺激动剂诱导的雄性大鼠体温过低,对雄性大鼠中 Remoxipride (MS-M25923) 的多巴胺 D2 受体阻断活性仅起微弱作用,无法模拟 Remoxipride 的非典型抗精神病药特征,可用于精神障碍的研究。

生物实验数据

生物活性 FLA-797 is a blood-brain barrier-penetrant dopamine D2 receptor blocker with very low affinity for dopamine D1 receptors that selectively binds to and blocks postsynaptic dopamine D2 receptors, induces catalepsy in male rats, blocks dopamine agonist-induced hypothermia in male rats, exerts only a weak effect on the dopamine D2 receptor-blocking activity of Remoxipride (MS-M25923) in male rats, fails to mimic the atypical antipsychotic profile of Remoxipride, and can be used for research on psychiatric disorders.
IC50 & Target

D2 Receptor

 

D1 Receptor

 

体外研究
(In Vitro)

FLA-797 (60 分钟) 在大鼠纹状体匀浆中对多巴胺 D2 受体表现出高选择性亲和力 (Ki = 0.49 nM),其亲和力远高于对 D1 受体的亲和力。

体内研究
(In Vivo)

FLA-797 在给大鼠腹腔注射 40 μmol/kg remoxipride 后 20 分钟时,血浆浓度达 0.6 nM。
FLA-797 (0.02-20 μmol/kg;腹腔注射;Apomorphine (MS-M00438) 给药前 60 分钟单次给药) 可强效阻断大鼠中 Apomorphine 诱导的过度活动 (ED50 = 0.06 μmol/kg i.p.) 与刻板行为,其阻断过度活动的效力比 Remoxipride 高约 15-20 倍。
FLA-797 (0.01-1 μmol/kg;腹腔注射;单剂量,于 Apomorphine 给药前 30 分钟给予) 可阻断大鼠由 Apomorphine 诱导的低体温,其腹腔注射 ED50 为 0.3 μmol/kg,效力比 Remoxipride 高约 3 倍。
FLA-797 (0.04-0.5 μmol/kg;腹腔注射、皮下注射;测试前 60 分钟单次给药) 可强效阻断大鼠中 d-苯丙胺诱导的运动行为,其腹腔注射的 ED50 为 0.5 μmol/kg,皮下注射的 ED50 为 0.04 μmol/kg,经相应给药途径的效力分别比 Remoxipride 高约 6 倍和 25 倍。
FLA-797 (0.63-20 μmol/kg;腹腔注射、皮下注射、静脉注射;单次给药) 可强效诱导大鼠出现僵住症,其 ED50 值范围为皮下注射<0.3 μmol/kg (网格试验) 至腹腔注射 3.1 μmol/kg (网格试验),且根据给药途径的不同,其效力是 Remoxipride 的至少 40-200 倍。

Animal Model: Sprague-Dawley (male, 55-75 days old, 260-350 g, challenged with Apomorphine 1 mg/kg s.c.)
Dosage: 0.02 μmol/kg; 0.05 μmol/kg; 0.1 μmol/kg; 0.2 μmol/kg; 0.5 μmol/kg; 1 μmol/kg; 2 μmol/kg; 5 μmol/kg; 10 μmol/kg; 20 μmol/kg;
Administration: i.p.; single dose 60 minutes prior to apomorphine
Result: Had an ED50 of 0.06 μmol/kg i.p.
for blocking Apomorphine-induced hyperactivity.
Had an ED50 of 0.32 μmol/kg i.p.
for blocking Apomorphine-induced oral stereotypies.
Was approximately 15-20 times more effective than Remoxipride at blocking hyperactivity, with a stereotypy/hyperactivity ratio of 5.3.
Animal Model: Sprague-Dawley (male, 55-75 days old, 260-350 g, challenged with Apomorphine 1 mg/kg s.c.)
Dosage: 0.025 μmol/kg; 0.05 μmol/kg; 0.1 μmol/kg; 0.25 μmol/kg; 0.5 μmol/kg; 1 μmol/kg; 2.5 μmol/kg; 5 μmol/kg; 10 μmol/kg
Administration: i.p.; single dose
Result: Had an ED50 of 0.3 μmol/kg i.p.
for blocking Rpomorphine-induced hypothermia, making it approximately three times more effective than Remoxipride.
When administered 60 minutes prior to Apomorphine, its ED50 increased to ~1.7 μmol/kg i.p.
Animal Model: Sprague-Dawley (male, 55-75 days old, 260-350 g, challenged with d-amphetamine 1.5 mg/kg i.p.)
Dosage: 0.25 μmol/kg; 1 μmol/kg; 2.5 μmol/kg
Administration: i.p.; single dose 60 minutes prior to testing
Result: Had an ED50 of 0.5 μmol/kg
for blocking d-amphetamine-induced locomotion.
Was approximately six times more effective than Remoxipride via intraperitoneal administration.
Animal Model: Sprague-Dawley (male, 55-75 days old, 260-350 g, challenged with d-amphetamine 1.5 mg/kg i.p.)
Dosage: 0.01 μmol/kg; 0.05 μmol/kg; 0.1 μmol/kg; 0.25 μmol/kg; 1 μmol/kg
Administration: s.c.; single dose 60 minutes prior to testing
Result: Had an ED50 of 0.04 μmol/kg
for blocking d-amphetamine-induced locomotion.
Was approximately 25 times more effective via subcutaneous administration.
Completely suppressed d-amphetamine-induced motor activity at a dose of 0.25 μmol/kg s.c.
Animal Model: Sprague-Dawley (male, 55-75 days old, 260-350 g)
Dosage: 0.63 kg/μmol; 1.25 kg/μmol; 2.5 kg/μmol; 5 kg/μmol; 10 kg/μmol; 20 μmol/kg
Administration: i.p.; single dose; s.c.; single dose; i.v.; single dose
Result: Had ED50 values for inducing bar test catalepsy of 0.9 μmol/kg i.p., 0.5 μmol/kg s.c., and 0.6 μmol/kg i.v.
Had ED50 values for inducing vertical grid test catalepsy of 3.1 μmol/kg i.p., <0.3 μmol/kg s.c., and 0.4 μmol/kg i.v.
Was 40 to at least 200 times more effective than Remoxipride at inducing catalepsy depending on administration route, with a stereoselective effect (the (+)-isomer failed to induce catalepsy at 20 μmol/kg i.p.).
Produced immediate catalepsy lasting the full 240-minute observation period at a 20 μmol/kg i.p.
or 2.5 μmol/kg i.v.
dose.

化学信息

分子量 357.24
分子式 C15H21BrN2O3
CAS No. 84226-14-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础